Background
In recent years, cancer immunotherapy, such as programmed death receptor 1 (PD-1) and programmed death-ligand 1 (PD-L1) monoclonal antibodies, has shown promising therapeutic outcomes in cancer. [1] [2] [3] [4] [5] T-cell immunoglobulin mucin-3 (TIM-3) is another important cancer immune checkpoint. 6 Patients treated with anti-PD-1 or anti-PD-L1 monoclonal antibodies will face the resistance problems. Koyama et al 6 reported TIM-3 expression was increased when patients faced the anti-PD-1 adaptive resistance.
Introduction to TIM-3
TIM-3, also known as HAVCR2, belongs to the TIM gene family. In humans, the TIM family includes TIM-1, TIM-3, and TIM-4 and is located on chromosome 5q33.2. In mice, the TIM family includes TIM-1 to TIM-8 and is located on chromosome 11B1.1. 7-9 TIM-3 is a type I membrane protein and consists of 281 amino acids. It comprises an extracellular domain, a single transmembrane domain, and a C-terminal cytoplasmic tail. [9] [10] [11] [12] [13] TIM-3 has four ligands, including galectin-9 (Gal-9), carcinoembryonic antigen cell adhesion molecule 1 (CEACAM-1), high-mobility group protein B1 (HMGB1), and phosphatidylserine (PS).
14 Gal-9 was the first to be identified. It is a carbohydrate binding protein, specifically recognizing the structure of N-linked sugar chains in the TIM-3 immunoglobulin variable (IgV) domain. 15 TIM-3/Gal-9 can inhibit cancer immunity by negatively regulating T-cell immunity. The connection of the TIM-3 IgV submit your manuscript | www.dovepress.com
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He et al domain with Gal-9 can terminate T helper 1 (Th1) immune responses. 10 TIM-3 could induce immunological tolerance. 10, 16 Its molecules are related to asthma, food allergy, and autoimmune disease, such as multiple sclerosis and rheumatoid arthritis. 7, 16 TIM-3 could also inhibit the immune responses of T cells and was associated with immune exhaustion, which induced chronic viral infection. 12, 13, 15 TIM-3 and cancer immunity TIM-3 inhibited antitumor immunity by mediating T-cell exhaustion. 15 TIM-3+ CD8 + T cells exhibit impaired Stat5 and p38 signaling pathway. Blocking the TIM-3 pathway enhanced cancer immunity and increased the production of interferon-gamma (IFN-γ) in T cells. 17 In in vitro and in vivo models, the expression of CD8
+ TIM-3+ T cells was correlated with PD-1 expression. TIM-3 was constitutively expressed on innate immune cells and could suppress innate antitumor immunity. TIM-3 inhibited the proliferation and effector of cytokine production, such as interleukin-2 (IL-2).
18-20 PD-1 and TIM-3 positive CD8 + T cells produced less IFN-γ than TIM-3 negative CD8 + T cells. 21 Anti-TIM-3 antibodies could also increase IFN-γ of peripheral NK cells. 22 Mast cells expressing TIM-3 could be activated through an ITAM-containing receptor for IgE (FcepsilonRI), using signaling pathways analogous to those in T cells. TIM-3 acts at a receptor-proximal point to enhance Lyn kinase-dependent signaling pathways that modulate both immediate-phase degranulation and latephase cytokine production downstream of FcepsilonRI ligation. 9 TIM-3 could be detected in non-small cell lung cancer (NSCLC), 22 head and neck cancer, 31 and so on. In myelogenous leukemia (AML), upregulated TIM-3 during AML could reduce cytokine production. Coexpression of PD-1 and TIM-3 was correlated with AML progression. 18 In follicular B-cell non-Hodgkin lymphoma, TIM-3 was expressed on nearly 35% of lymph node CD4 + and CD8
+ T cells and could mediate T-cells exhaustion.
32
In glioma patients, TIM-3 was correlated with cancer immune escape and might be a potent target. 33 In gastric cancer, TIM-3 could promote disease progression, 34 and Gal-9 and TIM-3 expressed on tumor cells might be a potential, independent prognostic factor. Decreased Gal-9 and increased TIM-3 were associated with a poor prognosis in gastric cancer.
35 PD-1+ and TIM-3+ CD8 + T cells could impair the functioning of CD8 + T cells in gastric cancer. 21, 36 In colorectal cancer, upregulation of TIM-3 could restrict T-cell responses and might participate in tumorigenesis.
The expression of TIM-3 might be an independent prognostic factor for colorectal cancer. 27 TIM-3 was correlated with the progression of colorectal cancer and could be a potential therapeutic target for the disease.
25 PD-1 and TIM-3 could impair surgery colorectal cancer patients' cell-mediated immunity. 28 In NSCLC patients, TIM-3 was expressed on about 30% of CD8 + tumor-infiltrating lymphocytes (TILs) and 60% of CD4 + FoxP3+ TILs. TIM-3+ FoxP3+ Tregs were correlated with the lung cancer stages.
37 TIM-3 expression in NK cells was related to disease progression of lung cancer.
38
In prostate cancer, TIM-3 could affect disease development and progression. 39, 40 In renal cell carcinoma (RCC), TIM-3 expressed on cancer cells and in myeloid cells could inhibit cancer immunity. 41 In ovarian cancer, TIM-3 could negatively regulate various T-cell subsets. TIM-3 expression on CD4
+ T cells could serve to predict the outcome of anticancer therapies. 30 In cervical cancer, the expression of TIM-3 in tumor cells might be a potential prognostic factor and could promote metastases.
29
Targeting TIM-3 in cancer TIM-3 could be a promising target in cancer because of its expression on a variety of T cells. 16 TIM-3 was also expressed on myeloid cells, such as DCs, macrophages, and monocytes. TIM-3 has an important role in innate immune cell-mediated antitumor immune responses. 16, 42 An increasing number of preclinical studies have reported that TIM-3 could improve the outcomes of cancer immunotherapy (Table 1) . TIM-3 inhibitors have shown similar efficacy as that of PD-1 inhibitors in preclinical research. 44 It was reported that PD-1 antibodies may lead to an increase in TIM-3 expression in in vivo models of lung cancer, which showed TIM-3 might be a marker of PD-1 blocking antibody resistance. 6 PD-1, TIM-3, and LAG-3 were upregulated on tumor-associated antigen-specific T cells in HCC tissues. PD-1, TIM-3, or LAG-3 inhibitors could enhance T cells' response to tumor antigens, and had a synergistic function. 52 TIM-3+ PD-1+ CD8 + TILs inhibited the production of cytokines, such as IFN-γ, tumor necrosis factor-alpha (TNF-α), and IL-2. 51 The combined use of TIM-3 blockade with PD-1 blockade could be more effective than blockade of either the TIM-3 or PD-1 alone. 6, [17] [18] [19] 43, 44, 48, 49, 51, 53 Currently, many clinical trials are focusing on TIM-3 as a new approach to the treatment of cancer (Table 2) .
Cancer immunotherapy has shown promising therapeutic outcomes. T-cell checkpoint inhibitor is one of the most promising new therapeutic approaches in cancer. TIM-3 
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